AC Immune S.A. (United States) is listed on the Nasdaq and has a market capitalization of $279.92 million, with shareholders equity totaling $44.00 million.
The company employs approximately 123 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, AC Immune S.A. reported $24.51 million in revenue, generating net income of $-92.83 million.
Key financial metrics include a P/E ratio of -3.02, a price-to-book (P/B) ratio of 6.36, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker ACIU.